Cargando…
Pharmacogenomics of Lithium Response in Bipolar Disorder
Despite being the most widely studied mood stabilizer, researchers have not confirmed a mechanism for lithium’s therapeutic efficacy in Bipolar Disorder (BD). Pharmacogenomic applications may be clinically useful in the future for identifying lithium-responsive patients and facilitating personalized...
Autores principales: | Vecera, Courtney M., Fries, Gabriel R., Shahani, Lokesh R., Soares, Jair C., Machado-Vieira, Rodrigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063790/ https://www.ncbi.nlm.nih.gov/pubmed/33804842 http://dx.doi.org/10.3390/ph14040287 |
Ejemplares similares
-
Inflammatory signaling mechanisms in bipolar disorder
por: Jones, Gregory H., et al.
Publicado: (2021) -
Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses
por: Machado-Vieira, Rodrigo, et al.
Publicado: (2021) -
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
por: Vecera, Courtney M., et al.
Publicado: (2023) -
The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample
por: Oedegaard, Ketil J., et al.
Publicado: (2016) -
Pharmacogenomic Characterization in Bipolar Spectrum Disorders
por: Fortinguerra, Stefano, et al.
Publicado: (2019)